

## Bersanlimab

Cat. No.:	HY-P99473
CAS No.:	1987854-08-9
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects <sup>[1]</sup> .		
In Vitro	BI-505 (1 ng/mL-1000 µg/mL) dose-dependently induces programmed cell death (PCD) in ICAM-1-expressing Ramos, Raji, and Daudi lymphoma cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	Bersanlimab (BI-505; 20 mg/kg; i.p.; twice-weekly; for 21 days) significantly reduces tumor growth and prolongs animal survival <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	SCID mice injected with ARH-77 cells <sup>[1]</sup>	
	Dosage:	20 mg/kg	
	Administration:	i.p.; twice-weekly; for 21 days	
	Result:	Significantly reduced tumor growth and prolonged animal survival.	

### REFERENCES

[1]. Niina Veitonmäki, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA